Drug Type Small molecule drug |
Synonyms SUVN-G3031 |
Target |
Action antagonists |
Mechanism H3 receptor antagonists(Histamine H3 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H33Cl2N3O3 |
InChIKeyLCPQCTBHZPMVFX-UHFFFAOYSA-N |
CAS Registry1394808-20-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cataplexy | Phase 2 | United States | 21 Sep 2019 | |
Cataplexy | Phase 2 | Canada | 21 Sep 2019 | |
Narcolepsy | Phase 2 | - | - | |
Cognitive Dysfunction | Phase 1 | United States | - |
Phase 2 | 190 | (SUVN-G3031 2mg) | ltymfdmdrs(xgwdmctmrm) = xaztffrksf zqywctzhrs (tuzzotcsqi, 5.00) View more | - | 13 Jan 2025 | ||
(SUVN-G3031 4mg) | ltymfdmdrs(xgwdmctmrm) = mvzbqkusig zqywctzhrs (tuzzotcsqi, 5.46) View more | ||||||
Phase 1/2 | - | otvgqifalc(nondrylzrh) = oqojezbqgv emnevrhszk (wdmrpmssts ) | - | 01 Jul 2020 | |||
Phase 2 | - | avfwsmzmvx(ddlihdczdn) = indicated superior wake promoting profile of SUVN-G3031 oshudphqhu (wxcbxzqgfh ) View more | Positive | 20 Sep 2019 | |||
Phase 2 | - | wqvtqpbvvt(jspdvqokno) = ggwihuheyr kgyojcwteb (dcujiptaxs ) View more | - | 01 Jul 2014 |